<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263572</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0792</org_study_id>
    <nct_id>NCT03263572</nct_id>
  </id_info>
  <brief_title>Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <official_title>Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if the combination of blinatumomab and
      ponatinib can help to control Philadelphia chromosome-positive acute lymphoblastic leukemia
      (Ph+ ALL); BCR-ABL-positive ALL; or ALL that has come back (relapsed) or has not responded to
      treatment (refractory). Ph+ and BCR-ABL positive are types of genetic mutations (changes).
      The safety of this drug combination will also be studied.

      This is an investigational study. Blinatumomab is FDA approved and commercially available for
      the treatment of other types of ALL. Ponatinib is FDA approved and commercially available for
      the treatment of several types of leukemia, including some types of Ph+ ALL. It is
      investigational to use the study drugs in combination with each other.

      The study doctor can describe how the study drugs are designed to work.

      Up to 60 participants will be enrolled in this study. All will take part at MD Anderson.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Drug Administration:

      Each cycle is 6 weeks. The first cycle is called an Induction Cycle, in which the study drugs
      are designed to create a response from the disease. Cycles 2-5 are called Consolidation
      Cycles, in which the drugs are designed to keep that disease response going. Cycles 6 and
      beyond are called Maintenance Cycles, in which just one study drug will be given to help keep
      the disease under control.

      If you are found to be eligible to take part in this study, you will receive a central venous
      catheter (CVC) if you do not already have one. A CVC is a sterile flexible tube that will be
      placed into a large vein while you are under local anesthesia. Your doctor will explain this
      procedure to you in more detail, and you will be required to sign a separate consent form for
      this procedure.

      You will receive blinatumomab by vein non-stop on Days 1-28 of Cycles 1-5. Blinatumomab will
      be delivered by a small pump, which you will carry with you for the whole time you receive
      the drug. This allows you to receive the drug constantly over a long period of time. You will
      be given a shoulder or belt bag to hold the pump and infusion bag. You will be able to wear
      regular clothes, walk around, and perform daily living activities. You will be given
      instructions for taking a shower and other activities. However, because the line must be kept
      free of infection and connected to the pump at all times, some activities (like swimming) are
      not allowed during the study. The study staff will give you more information on activities
      you should not do while receiving the drug.

      If you have not been previously treated, you may need to stay in the hospital for your
      blinatumomab doses on Days 1-6 of Cycle 1 and Days 1 and 2 of Cycle 2. Your doctor will
      discuss this option with you.

      If you do not have to stay overnight in the hospital for your doses, you will need to return
      to the clinic at certain times to have the infusion bag changed. This is performed
      approximately every 48 hours.

      You will receive dexamethasone by vein over 30 minutes within 1 hour before the start of each
      treatment cycle and at the time of any increase in dose to prevent side effects associated
      with blinatumomab treatment. If side effects do occur, you will receive dexamethasone by
      mouth or orally or by vein for 3 to 7 days.

      If you have not been previously treated, on Days 1, 15, and 29 of Cycles 1-4, you will also
      receive methotrexate and cytarabine. Methotrexate and cytarabine will be given intrathecally
      (by spinal tap) during a short infusion. If you are found to have disease in the brain/spinal
      cord, you may need to receive more doses after Cycle 4.

      You will take ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of
      no ponatinib. Beginning with Cycle 2, you will take ponatinib by mouth every day while you
      are on study.

      You will take between 1-2 tablets of ponatinib by mouth daily. The dose will be adjusted
      based on the status of the disease and if you experience any side effects with the higher
      dose. You should avoid taking antacids 2 hours before or after ponatinib. You doctor will
      discuss other drugs that you cannot take with ponatinib.

      You will be given standard drugs to help decrease the risk of side effects. You may ask the
      study staff for information about how the drugs are given and their risks.

      Length of Study Participation:

      You will receive blinatumomab for up to 5 cycles. You may continue to receive ponatinib for
      as long as the doctor thinks it is in your best interest. You will no longer be able to take
      the study drug(s) if the disease gets worse, if intolerable side effects occur, the study
      doctor thinks it is in your best interest to stop taking part in the study, the study is
      cancelled, or if you are unable to follow study directions.

      Your participation on the study will be over after the follow-up visits.

      Study Visits:

      One (1) or two (2) times each week during Cycle 1, then every 1-3 weeks during Cycles 2-5,
      then every 4 to 8 weeks after that, blood (about 2-3 teaspoons) will be drawn for routine
      tests.

      On Days 28 and 42 of Cycle 1, then on Day 1 of Cycles 3 and 5, then every 3-6 months after
      that, you will have a bone marrow biopsy/aspiration for cytogenetic testing and to check the
      status of the disease.

      Every 3-6 months, either your blood or bone marrow sample will also be used for biomarker
      testing.

      Follow-up:

      About 30 days after your last dose of study drug, you may be called by a member of the study
      staff and asked about how you are feeling and about any side effects you may be experiencing.
      This call should last about 5-10 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2017</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Molecular Response (CMR) Rate in Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</measure>
    <time_frame>18 weeks</time_frame>
    <description>CMR defined as normalization of the peripheral blood and bone marrow with less than 5% blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 109/L or above, and platelet count of 100 x 109/L, and CR with RT-PCR negativity for BCR-ABL.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response (OR) Rate in Relapsed/Refractory ALL Disease</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall response defined as the percentage of patients achieving CR or CRi</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First cycle is Induction Cycle, Cycles 2-5 are Consolidation Cycles, and Cycles 6 and beyond are Maintenance Cycles. Each cycle is 6 weeks.
Blinatumomab by vein non-stop on Days 1-28 of Cycles 1-5.
Dexamethasone by vein given within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment. If side effects do occur, Dexamethasone given by mouth or orally or by vein for 3 to 7 days.
Methotrexate and Cytarabine given intrathecally on Days 1, 15, and 29 of Cycles 1-4.
Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Relapsed/Refractory ALL Disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First cycle is Induction Cycle, Cycles 2-5 are Consolidation Cycles, and Cycles 6 and beyond are Maintenance Cycles. Each cycle is 6 weeks.
Blinatumomab by vein non-stop on Days 1-28 of Cycles 1-5.
Dexamethasone by vein given within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment. If side effects do occur, Dexamethasone given by mouth or orally or by vein for 3 to 7 days.
Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate given at 12 mg (6 mg if intra-ommaya) on Days 1, 15, and 29 of Cycles 1-4.
Total number of prophylactic intrathecal treatments for previously untreated patients will be 12.
A total of 3 given with each course of Blinatumomab on day 1 (+/- 3 days), day 15 (+/- 3 days) and day 29 (+/- 3 days) until total number reached.</description>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 100 mg on Days 1, 15, and 29 of Cycles 1-4.
Total number of prophylactic intrathecal treatments for previously untreated patients will be 12.</description>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Cytosar</other_name>
    <other_name>DepoCyt</other_name>
    <other_name>Cytosine Arabinosine Hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Blinatumomab administered as continuous intravenous infusion at a dose of 28 Î¼g/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle for up to 5 cycles (one induction and up to 4 consolidations).</description>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
    <arm_group_label>Relapsed/Refractory ALL Disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Dexamethasone by mouth or vein given for 3 to 7 days within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment.</description>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
    <arm_group_label>Relapsed/Refractory ALL Disease</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study.
During cycle 1, Ponatinib 30 mg given by mouth daily from Day 1 till Day 28 of Blinatumomab.
Subsequent courses Ponatinib 30 mg by mouth daily continuously without interruptions unless due to toxicity. In patients who achieved CMR, ponatinib should be further reduced to 15 mg per day unless judged necessary to stay on 30 mg and after discussion with the PI.</description>
    <arm_group_label>Newly Diagnosed Ph-Positive and/or BCR-ABL-Positive ALL</arm_group_label>
    <arm_group_label>Relapsed/Refractory ALL Disease</arm_group_label>
    <other_name>Iclusig</other_name>
    <other_name>AP24534</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of one of the following: a) Patients &gt;/= 60 years of age with previously
             untreated Ph-positive ALL [either t(9;22) and/or BCR-ABL positive] (includes patients
             initiated on first course of therapy before cytogenetics known): This patient could
             have received one or two courses of chemotherapy with or without other TKIs and still
             eligible; b) If they achieved CR, they are assessable only for event-free and overall
             survival; or c) If they failed to achieve CR, they are assessable for CR, event-free,
             and overall survival; d) Patients &gt;/= 18 years of age with relapsed/refractory
             Ph-positive ALL

          2. Performance status &lt;/=2 (ECOG Scale)

          3. Adequate liver function as defined by the following criteria: a) Total serum bilirubin
             &lt;/= 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome, b) Alanine
             aminotransferase (ALT) &lt;/= 3 x ULN, and c) Aspartate aminotransferase (AST) &lt;/= 3 x
             ULN

          4. Adequate pancreatic function as defined by the following criteria: a) Serum lipase and
             amylase &lt;/= 1.5 x ULN

          5. For females of childbearing potential, a negative urine pregnancy test must be
             documented prior to randomization

          6. Female patients who: Are postmenopausal for at least 1 year before the screening
             visit, OR Are surgically sterile, OR If they are of childbearing potential, agree to
             practice 2 effective methods of contraception, at the same time, from the time of
             signing the informed consent through 4 months after the last dose of study drug, or
             agree to completely abstain from heterosexual intercourse

          7. Male patients, even if surgically sterilized (i.e., status post-vasectomy), who: Agree
             to practice effective barrier contraception during the entire study treatment period
             and through 4 months after the last dose of study drug, OR Agree to completely abstain
             from heterosexual intercourse

          8. Adequate cardiac function as assessed clinically by history and physical examination

          9. Signed informed consent

        Exclusion Criteria:

          1. Active serious infection not controlled by oral or intravenous antibiotics.

          2. History of acute pancreatitis within 1 year of study or history of chronic
             pancreatitis

          3. History of alcohol abuse

          4. Uncontrolled hypertriglyceridemia (triglycerides &gt; 450mg/dL)

          5. Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or
             squamous cell carcinoma) that in the investigator's opinion will shorten survival to
             less than 1 year.

          6. Active Grade III-V cardiac failure as defined by the New York Heart Association
             Criteria.

          7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically
             including, but not restricted to: Any history of myocardial infarction (MI), stroke,
             or revascularization; Unstable angina or transient ischemic attack prior to
             enrollment; Congestive heart failure prior to enrollment, or left ventricular ejection
             fraction (LVEF) less than lower limit of normal per local institutional standards
             prior to enrollment; Diagnosed or suspected congenital long QT syndrome; Any history
             of clinically significant atrial or ventricular arrhythmias (such as atrial
             fibrillation, ventricular tachycardia, ventricular fibrillation, or Torsades de
             pointes) as determined by the treating physician; Prolonged QTc interval on pre-entry
             electrocardiogram (&gt; 470 msec) unless corrected after electrolyte replacement;

          8. Continued from #7: Any history of venous or arterial thromboembolism including deep
             venous thrombosis or pulmonary embolism. Patients with a history of treated prior
             superficial or catheter associated will not be considered as significant embolism and
             after discussion with PI will not be excluded from eligibility. Uncontrolled
             hypertension (diastolic blood pressure &gt;90mmHg; systolic &gt;140mmHg). Patients with
             hypertension should be under treatment on study entry to effect blood pressure control

          9. Patients currently taking drugs that are generally accepted to have a risk of causing
             Torsades de Pointes (unless these can be changed to acceptable alternatives)

         10. Taking any medications or herbal supplements that are known to be strong inhibitors of
             CYP3A4 within at least 14 days before the first dose of ponatinib in patients with
             newly diagnosed only.

         11. History or presence of clinically relevant CNS pathology such as epilepsy, childhood
             or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia,
             Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.
             Patients with active CNS leukemia will be excluded

         12. Current autoimmune disease or history of autoimmune disease with potential CNS
             involvement

         13. Treatment with any investigational antileukemic agents or chemotherapy agents in the
             last 7 days before study entry, unless full recovery from side effects has occurred or
             patient has rapidly progressive disease judged to be life-threatening by the
             investigator.

         14. Pregnant and lactating women will not be eligible; women of childbearing potential
             should have a negative urine pregnancy test prior to entering on the study and be
             willing to practice methods of contraception. Women do not have childbearing potential
             if they have had a hysterectomy or are postmenopausal without menses for 12 months. In
             addition, men enrolled on this study should understand the risks to any sexual partner
             of childbearing potential and should practice an effective method of birth control.

         15. History of significant bleeding disorder unrelated to cancer, including: Diagnosed
             congenital bleeding disorders (e.g., von Willebrand's disease); Diagnosed acquired
             bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies)

         16. Patients with documented significant pleural or pericardial effusions unless they are
             thought to be secondary to their leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elias Jabbour, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elias Jabbour, MD</last_name>
    <phone>713-792-4764</phone>
    <email>CR_Study_Registration@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Research Operations</last_name>
      <email>CR_Study_Registration@mdanderson.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant neoplasms stated as primary lymphoid haematopoietic</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>Philadelphia chromosome-positive acute lymphoblastic leukemia</keyword>
  <keyword>Ph+ ALL</keyword>
  <keyword>BCR-ABL-positive ALL</keyword>
  <keyword>ALL relapsed or refractory</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Ara-C</keyword>
  <keyword>Cytosar</keyword>
  <keyword>DepoCyt</keyword>
  <keyword>Cytosine arabinosine hydrochloride</keyword>
  <keyword>Blinatumomab</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Decadron</keyword>
  <keyword>Ponatinib</keyword>
  <keyword>Iclusig</keyword>
  <keyword>AP24534</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Philadelphia Chromosome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
    <mesh_term>Ponatinib</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

